Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00525824 · ClinicalTrials.gov registry record · Phase 3
12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
A Phase 3 study of Atherosclerosis and Hypercholesterolemia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,743
- Enrollment target
- 9
- Study locations
NCT00525824: Completed Phase 3 study of Atherosclerosis and Hypercholesterolemia, sponsored by AstraZeneca.
NCT00525824 is a Phase 3 study of Atherosclerosis and Hypercholesterolemia that has completed, run by AstraZeneca. The registered enrollment target is 1,743 participants, above the 1,040-participant average among 69 other Atherosclerosis trials with a reported enrollment target (68% higher). The trial reports 9 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00525824, a Phase 3 study of Atherosclerosis and Hypercholesterolemia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,743 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to determine whether treatment of Rosuvastatin (CRESTOR™) or Simvastatin given as monotherapy or given in combination with Ezetimibe, will lower the Low Density Lipoprotein Cholesterol (LDL-C) in patients with Hypercholesterolaemia and Coronary Heart Disease (CHD) or a CHD Risk Equivalent, Atherosclerosis or a 10-year CHD Risk of \>20%
Primary Outcome
Percent change in LDL-C = (Combination treatment value - Baseline value)/Baseline value\*100
Conditions Studied
Interventions
- DRUG Simvastatin
- DRUG Ezetimibe
- DRUG Rosuvastatin (Crestor)
Study Locations (9)
Other
- Research Site - Buenos Aires
- Research Site - Santiago
- Research Site - Brentwood
- Research Site - Brentwood
- Research Site - Zwinderen
- Research Site - Brentwood
Tennessee
- Research Site - Brentwood
São Paulo
- Research Site - São Paulo
San Isidro Lima
- Research Site - Lima
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,743 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
What the finished NCT00525824 record still lists
NCT00525824 is an interventional study that assigns participants to a tested intervention. Its 1,743 participants enrollment target places it among the larger protocols in the corpus, above the 1,040-participant average among 69 other Atherosclerosis trials with a reported enrollment target (68% higher).
The record links to 3 conditions, with Atherosclerosis appearing as the primary indexed condition, and to 3 interventions - of which Simvastatin is the first listed.
NCT00525824 lists 9 locations in 4 states (Other, Tennessee, São Paulo).
Frequently Asked Questions
What is clinical trial NCT00525824 about?
NCT00525824 is a clinical study titled "12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe". The purpose of this study is to determine whether treatment of Rosuvastatin (CRESTOR™) or Simvastatin given as monotherapy or given in combination with Ezetimibe, will lower the Low Density Lipoprotein Cholesterol (LDL-C) in patients with Hypercholesterolaemia and Coronary Heart Disease (CHD) or a C...
What is the current status of trial NCT00525824?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,743 participants. The study started on 2007-08. Estimated completion is 2008-09.
What conditions does trial NCT00525824 study?
This clinical trial studies the following conditions: Atherosclerosis, Hypercholesterolemia, Coronary Heart Disease.
What interventions are being tested in trial NCT00525824?
The interventions under investigation include: Simvastatin (DRUG), Ezetimibe (DRUG), Rosuvastatin (Crestor) (DRUG).
Who is sponsoring clinical trial NCT00525824?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00525824 being conducted?
This trial has 9 study locations across Tennessee, São Paulo, San Isidro Lima. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00525824's enrollment target sits among peer trials
1,743 12th of 69 higher than 58 of 69 other Atherosclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
COMPLETED · Phase 3
-
High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly
COMPLETED · Phase 3
-
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
COMPLETED · Phase 3
-
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
COMPLETED · Phase 3
-
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
RECRUITING · Phase 4
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04712656 · 1,739 participants
Effects of CPAP Therapy on Blood Pressure and Heart Rate Variability in Obstructive Sleep Apnea
- NCT05934487 · 1,750 participants · NA
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
- NCT06954337 · 1,750 participants · NA
MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial
- NCT07183527 · 1,750 participants · NA
Hybrid Type I Effectiveness-implementation Cluster Randomized Controlled Trial of CARES
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia